As research expands beyond amyloid and tau, experts discuss how novel biomarkers could identify multiple coexisting neurodegenerative pathologies and pave the way for more personalized treatment approaches based on each patient’s unique disease profile. [WATCH TIME: 9 Minutes]
As research moves toward treating Alzheimer disease before symptoms emerge, experts highlight the potential of plasma biomarkers to identify at-risk individuals, guide clinical trial enrollment, and create a window for intervention before irreversible neuronal damage occurs. [WATCH TIME: 6 Mintes]
Experts discuss how plasma biomarkers may enable earlier detection of Alzheimer disease pathology, including in cognitively unimpaired individuals and those with subjective cognitive decline, while offering a more accessible alternative to CSF and PET-based assessment. [WATCH TIME: 8 Minutes]
The director of NYU Langone’s Alzheimer’s Disease Research Center discussed noticeable advancements within the field of Alzheimer disease in recent years and how they contribute to gaining a better understanding of the disease. [WATCH TIME: 5 minutes]
The director of NYU Langone’s Alzheimer’s Disease Research Center and Center for Cognitive Neurology discussed current knowns and unknowns about the pathology of Alzheimer disease. [WATCH TIME: 4 minutes]
